This course was last updated on
April 30, 2019
CME credit has expired.

In this activity, Bruno Medeiros, MD, and Farhad Ravandi-Kashini, MD, discuss recent advances in the treatment of acute myeloid leukemia (AML). They discuss how new approvals have changed the paradigm for how AML is treated. A central topic in this program is how a better understanding of the molecular genetics of AML has led to new treatments. Dr. Medeiros and Dr. Ravandi-Kashini discuss the pathology and genetics that support the use of new targeted therapies, and the implications of findings from recent clinical trials.

Content Areas

  • Acute myeloid leukemia
  • Daunorubicin-cytarabine
  • Targeted treatment
  • FLT3 Tyrosine Kinase Inhibitors
  • Isocitrate Dehydrogenase Mutations
  • Apoptosis
  • CD33 monoclonal antibodies
  • Bispecific antibodies


Bruno Medeiros, MD
Bruno Medeiros, MD
Adjunct Clinical Associate Professor of Medicine
Department of Medicine, Hematology
Stanford Comprehensive Cancer Network
Stanford University
Stanford, California
Farhad Ravandi-Kashani, MD
Farhad Ravandi-Kashani, MD
MD Anderson Center/University of Texas
Department of Leukemia
Division of Cancer Medicine
Houston, Texas
Enter your information to begin.

Target Audience

This activity was developed for a national audience of hematologist-oncologists, oncology nurse practitioners, nurses, physician assistants, and other healthcare providers who treat patients with AML.

Cme credit

Available Credit: 1.00 AMA PRA Category 1 Credit™.
1.00 ANCC Contact Hour
Opens: April 30, 2019
Expires: April 29, 2020
Target Audience: Hematologist/Oncologists
Nurse Practitioners
Physician Assistants
Other Healthcare Providers
This activity is supported by an independent educational grant from Pfizer, Inc.